4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Improving Women's and Children's Health Via Biobanking and Electronic Registry (iELEVATE)

Improving Women's and Children's Health Via Biobanking and Electronic Registry (iELEVATE)

Study Description
Brief Summary:
Pregnancy related diseases and exposures in pregnancy are known risk factors for future disease. For example, women with a history of preeclampsia (a hypertensive disorder in pregnancy) and children born to these women are at increased risk of cardiovascular disease later in life. Yet, the mechanisms by which these long term health risks occur are unknown. Clearly, this presents a significant public health hazard as preventative and therapeutic interventions to block these pregnancy related diseases are limited. Current barriers to studying these long-term mechanisms in existing cohorts include 1) lack of paired long-term mother-child data, 2) lack of uniformly collected biosamples and 3) challenges in integrating data from multiple sources and institutions. In particular, data and biosample collection from rural and minority populations present significant challenges. The objective of the iELEVATE proposal is to expand and diversify a current biobank to accelerate long-term translational mechanistic and outcomes research in the vulnerable pregnancy population. We will accomplish this by establishing a widely available biorepository that will collect a first trimester blood and urine sample from pregnant women with a clinical data warehouse and e-registry to support long-term prospective cohort studies.

Condition or disease Intervention/treatment
Pregnancy Related Maternal-Fetal Relations Other: Blood sample Other: Urine sample Other: Pregnancy, maternal health, and fetal health data

Study Design
Layout table for study information
Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Improving Women's and Children's Health Via Biobanking and Electronic Registry
Actual Study Start Date : January 7, 2020
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : February 28, 2022
Arms and Interventions
Group/Cohort Intervention/treatment
Group 1
Pregnant women and their baby
Other: Blood sample
1st trimester blood sample for bio-bank

Other: Urine sample
1st trimester urine sample for bio-bank

Other: Pregnancy, maternal health, and fetal health data
Pregnancy, maternal health, and fetal health data

Outcome Measures
Primary Outcome Measures :
  1. 1.Number of Participants and Controls Enrolled in Biobank [ Time Frame: 2 years ] [ Time Frame: 2 years ]
    Create bio-bank of maternal blood,urine and data.


Biospecimen Retention:   Samples With DNA
1st trimester maternal blood and urine sample

Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pregnant woman in their first trimester.
Criteria

Inclusion Criteria:

Pregnant women in their first trimester (less than 14 weeks) and have the capacity to provide informed consent are eligible to participate

Exclusion Criteria:

Under 18 years old, known non-viable pregnancy at time of consent,inability to provide informed consent and diagnosis of a known infectious disease.

Contacts and Locations

Locations
Layout table for location information
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, Iowa
OB Gyn Associates, PC
Cedar Rapids, Iowa, United States, 52402
The Group Obstetrics & Gynecology Specialists, PC
Davenport, Iowa, United States, 52807
University of Iowa
Iowa City, Iowa, United States, 52242
West Des Moines OB GYN Associates, PC
West Des Moines, Iowa, United States, 50266
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55414
United States, Wisconsin
Marshfield Clinic Research Institute
Wausau, Wisconsin, United States, 55401
Sponsors and Collaborators
Mark Santillan
National Institutes of Health (NIH)
Investigators
Layout table for investigator information
Principal Investigator: Mark Santillan, PhD, MD University of Iowa
Tracking Information
First Submitted Date May 2, 2019
First Posted Date May 6, 2019
Last Update Posted Date May 5, 2021
Actual Study Start Date January 7, 2020
Estimated Primary Completion Date February 28, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: May 2, 2019)
1.Number of Participants and Controls Enrolled in Biobank [ Time Frame: 2 years ] [ Time Frame: 2 years ]
Create bio-bank of maternal blood,urine and data.
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Improving Women's and Children's Health Via Biobanking and Electronic Registry
Official Title Improving Women's and Children's Health Via Biobanking and Electronic Registry
Brief Summary Pregnancy related diseases and exposures in pregnancy are known risk factors for future disease. For example, women with a history of preeclampsia (a hypertensive disorder in pregnancy) and children born to these women are at increased risk of cardiovascular disease later in life. Yet, the mechanisms by which these long term health risks occur are unknown. Clearly, this presents a significant public health hazard as preventative and therapeutic interventions to block these pregnancy related diseases are limited. Current barriers to studying these long-term mechanisms in existing cohorts include 1) lack of paired long-term mother-child data, 2) lack of uniformly collected biosamples and 3) challenges in integrating data from multiple sources and institutions. In particular, data and biosample collection from rural and minority populations present significant challenges. The objective of the iELEVATE proposal is to expand and diversify a current biobank to accelerate long-term translational mechanistic and outcomes research in the vulnerable pregnancy population. We will accomplish this by establishing a widely available biorepository that will collect a first trimester blood and urine sample from pregnant women with a clinical data warehouse and e-registry to support long-term prospective cohort studies.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
1st trimester maternal blood and urine sample
Sampling Method Non-Probability Sample
Study Population Pregnant woman in their first trimester.
Condition
  • Pregnancy Related
  • Maternal-Fetal Relations
Intervention
  • Other: Blood sample
    1st trimester blood sample for bio-bank
  • Other: Urine sample
    1st trimester urine sample for bio-bank
  • Other: Pregnancy, maternal health, and fetal health data
    Pregnancy, maternal health, and fetal health data
Study Groups/Cohorts Group 1
Pregnant women and their baby
Interventions:
  • Other: Blood sample
  • Other: Urine sample
  • Other: Pregnancy, maternal health, and fetal health data
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Enrolling by invitation
Estimated Enrollment
 (submitted: May 2, 2019)
10000
Original Estimated Enrollment Same as current
Estimated Study Completion Date February 28, 2022
Estimated Primary Completion Date February 28, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

Pregnant women in their first trimester (less than 14 weeks) and have the capacity to provide informed consent are eligible to participate

Exclusion Criteria:

Under 18 years old, known non-viable pregnancy at time of consent,inability to provide informed consent and diagnosis of a known infectious disease.

Sex/Gender
Sexes Eligible for Study: Female
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT03938129
Other Study ID Numbers 201901749
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Mark Santillan, University of Iowa
Study Sponsor Mark Santillan
Collaborators National Institutes of Health (NIH)
Investigators
Principal Investigator: Mark Santillan, PhD, MD University of Iowa
PRS Account University of Iowa
Verification Date May 2021